Noema Pharma

We are pleased to announce the initiation of our Phase 2b Study with gemlapodect (NOE-105) in Tourette Syndrome.

The FPA is pleased to announce Noema Pharma's continued partnership as an Inspiration Level Sponsor! FPA Sponsors help us meet our mission of support, education, and advocacy for the facial pain community. We invite you to read this message from Noema Pharma: "Noema Pharma is a biotech company developing novel therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema initiated the Libra Study©, a clinical program to evaluate the effect of a potential novel therapy for the management of pain in patients with trigeminal neuralgia. Participation in the clinical study is currently open to people who suffer from trigeminal neuralgia and who are not fully benefiting from their current therapies. Additional information is available on the ClinicalTrials.gov website. Noema’s research and development focuses on understanding and meeting patient needs using novel therapies so patients can live their lives to the fullest. Noema is engaging in a full partnership with communities of patients, their families, caregivers, and health care providers to better understand and address patients’ needs." To learn more about Noema Pharma, visit https://noemapharma.com/ Last week, Noema Pharma presented a webinar on their clinical trial to evaluate the effect of basimglurant for the management of pain in patients with trigeminal neuralgia. Watch the recorded webinar by visiting https://lnkd.in/euKF35s2

Another exciting milestone as we progress our pipeline.

Are you an expert in GMP, self-motivated, and thrive in a fast-paced, small company environment? We’re looking for proactive problem-solvers who can work independently and are eager for new opportunities. If this sounds like you, we want to hear from you! Apply now via the link below.

As part of the Facial Pain Association's Research Initiative, we are committed to keeping you informed of efforts that may result in better treatment options for trigeminal neuralgia and other neuropathic facial pain. ⚡️ Do you have trigeminal neuralgia? Is your current treatment sub-optimal? If you answered yes to both, the Noema Pharma Libra Study may be an option for you. For US residents, visit https://lnkd.in/e4NGTYEF Find the closest center to you by visiting https://lnkd.in/eAX9mbMX The Facial Pain Association posts information about relevant medical studies and trials which may be of interest to people affected with neuropathic facial pain. These listings are provided as a convenience only and are not to be considered an endorsement or recommendation by FPA. The safety and scientific validity of a study listed on this site is the responsibility of the study sponsor and investigators. Learn more on our website at https://lnkd.in/gpsmjCrG

Will you be in Atlanta at this year's Epilepsy Foundation Pipeline Conference? We'll (NOEMA) be attending and presenting data supporting NOE-101 and our study in patients with Tuberous Sclerosis Complex (TSC) on Thursday, September 26th in Session VIII: Clinical Drugs at 3:30p. Come by - or reach out to connect!

Delighted to see Noema Pharma recognised as a TOP Swiss Biotech Startup

So pleased to have completed enrollment in our Phase 2B study of NOE-101! With the trial fully enrolled, we look forward to the milestone of reporting top-line data.

Proud to share this exciting news… the 5th P2 program to enter the clinic as we broaden our portfolio of first-in-disease transformational approaches targeting neuroscience based conditions, including women’s health.